Every cloud has a silver lining: Weather forecasting models could predict brain tumor growth

December 21, 2011

Ever wondered how meteorologists can accurately predict the weather? They use complex spatiotemporal weather models, i.e. mathematical equations that track the motions of the atmosphere through time and space, and combine them with incoming data streams from weather stations and satellites. Now, an innovative new study published in BioMed Central's open access journal Biology Direct has determined that the mathematical methodology used to assimilate data for weather forecasting could be used to predict the spread of brain tumors.

The authors from the Arizona State University and the Barrow Neurological Institute, Arizona, USA, wanted to prove that mathematical methods used in could be useful in clinical situations – not just in brain cancer, but also in other cancers and diseases. They chose to study glioblastoma multiforme (GBM), a malignant brain cancer.

GBM is the most common and most aggressive type of brain cancer. Despite treatment, average patient survival is less than 15 months from initial diagnosis, and it is largely resistant to chemo- and radiotherapy. GBM can quickly invade large, sensitive regions of the brain, which makes it almost impossible to remove via surgery and almost certain to recur afterwards. Because little progress has been made in this area, GBM is an important area to study, and is a particularly good cancer against which to test a mathematical model, as its dynamics involve complex geometry.

In addition to setting out to prove that good quantitative predictions of GBM growth and spread are possible, the authors wanted to provide uncertainty estimates. An algorithm previously developed for numerical weather prediction – a modern state estimation algorithm known as a Local Ensemble Transform Kalman Filter (LETKF) – was applied to two different mathematical models of the growth and spread of glioblastoma. Synthetic magnetic resonance images of a hypothetical tumor were used for this purpose.

Data assimilation techniques were then used to update the state vector, i.e. the initial condition of the glioblastoma growth model, by combining new observations with one or more prior forecasts. They then measured the feasibility of the model in individual patient cases for making short-term (60-day) forecasts of GBM spread and growth.

Despite this being a preliminary study, the authors were successful in demonstrating the feasibility of LETKF for short-term, clinically relevant predictions of the growth and spread of malignant . LETKF forecasting and data assimilation provides an accurate and computationally efficient way of updating the initial condition (state vector) of a complex spatiotemporal model with new quantitative measurements. The intelligent model can also take into account likely errors in model parameters and measurement uncertainties in magnetic resonance imaging.

Mark Preul, one of the leaders of the study, believes that LETKF should be considered for future efforts that use mathematical models for clinical purposes in individual patient cases. He said, "Though work remains before our approach can be seriously considered in clinical settings, an accurate forecast system for glioblastoma may prove useful for treatment planning and patient counseling."

Explore further: How brain tumors invade

More information: Accurate State Estimation from Uncertain Data and Models: An Application of Data Assimilation to Mathematical Models of Human Brain Tumors. Eric J Kostelich, Yang Kuang, Joshua M McDaniel, Nina Z Moore, Nikolay L Martirosyan and Mark C Preul Biology Direct (in press)

Related Stories

How brain tumors invade

December 12, 2011
Scientists have pinpointed a protein that allows brains tumors to invade healthy brain tissue, according to work published this week in the Journal of Experimental Medicine.

Patient receives first prescription for FDA-approved brain tumor treatment

December 5, 2011
(Medical Xpress) -- The University of Illinois Hospital is the first center in North America to prescribe a new FDA-approved treatment for patients with the most common and aggressive type of brain tumor, glioblastoma multiforme, ...

Glioblastoma multiforme in the Dock

November 14, 2011
Glioblastoma multiforme (GBM) is the most common malignant brain cancer in humans. Patients with GBM have a poor prognosis because it is a highly aggressive form of cancer that is commonly resistant to current therapies. ...

Recommended for you

What does hair loss have to teach us about cancer metastasis?

December 15, 2017
Understanding how cancer cells are able to metastasize—migrate from the primary tumor to distant sites in the body—and developing therapies to inhibit this process are the focus of many laboratories around the country. ...

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

Liquid biopsy results differed substantially between two providers

December 14, 2017
Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. Liquid biopsy is a new and noninvasive alternative ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.